UK Oncology Based In-vivo Cro Market Size & Outlook
UK oncology based in-vivo cro market, 2018-2030 (US$M)
Related Markets
UK oncology based in-vivo cro market highlights
- The UK oncology based in-vivo cro market generated a revenue of USD 95.4 million in 2023 and is expected to reach USD 172.6 million by 2030.
- The UK market is expected to grow at a CAGR of 8.8% from 2024 to 2030.
- In terms of segment, solid tumor was the largest revenue generating indication in 2023.
- Solid Tumor is the most lucrative indication segment registering the fastest growth during the forecast period.
Oncology based in-vivo cro market data book summary
| Market revenue in 2023 | USD 95.4 million |
| Market revenue in 2030 | USD 172.6 million |
| Growth rate | 8.8% (CAGR from 2023 to 2030) |
| Largest segment | Solid tumor |
| Fastest growing segment | Solid Tumor |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Solid Tumor |
| Key market players worldwide | Charles River Laboratories International Inc, Icon PLC, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Labcorp Holdings Inc, Wuxi AppTec Co Ltd, Evotec SE, Taconic Biosciences, The Jackson Laboratory |
Other key industry trends
- In terms of revenue, UK accounted for 7.2% of the global oncology based in-vivo cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany oncology based in-vivo cro market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 172.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Based In-vivo CRO Market Scope
Oncology Based In-vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK oncology based in-vivo cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based in-vivo cro market will help companies and investors design strategic landscapes.
Solid tumor was the largest segment with a revenue share of 47.17% in 2023. Horizon Databook has segmented the UK oncology based in-vivo cro market based on blood cancer, solid tumor covering the revenue growth of each sub-segment from 2018 to 2030.
The market in the UK is expected to grow at a lucrative rate owing to various initiatives laid by the government. For instance, in the UK there are two types of tax credit systems for small & medium companies and large-sized companies.
The large companies can claim around 30.0% deduction from their R&D expenditure. In the case of small & medium sized enterprises, it is 25.0% of the R&D expenditure. Outsourced preclinical services are expected to grow at a faster rate due to increasing demand for improved test outcomes at lower costs by pharmaceutical companies.
Pharmaceutical and biotech companies in the UK rely on in vivo services offered by CROs to help develop new medicines and meet the need for advanced new treatments. The National Centre for the Replacement, Refinement, & Reduction of Animals in Research (NC3Rs) was started by the UK government in 2004 to minimize the use of animals in research and improve animal welfare
Reasons to subscribe to UK oncology based in-vivo cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK oncology based in-vivo cro market databook
-
Our clientele includes a mix of oncology based in-vivo cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK oncology based in-vivo cro market , including forecasts for subscribers. This country databook contains high-level insights into UK oncology based in-vivo cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK oncology based in-vivo cro market size, by indication, 2018-2030 (US$M)
UK Oncology Based In-vivo CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
